Company: PSTV
Filing Date: 2025-04-23
Form Type: S-3/A
Source: 0001193125-25-091456
Chunk: 12

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: S-3/A
Chunk 12
---
 to 1,261,896,210 shares of common stock assuming the Series B Common
Stock Warrants are exercised pursuant to the zero exercise price provision.

Any sale of such shares may depress the market price of our common stock.
Sales of a substantial number of shares of our common stock by the selling stockholders in the public market could occur at any time. Whether as a result of sales of a substantial number of shares of our common stock by the selling stockholders or
the perception that such sales may occur, the market price of shares of our common stock could decline significantly and the volatility of the market price of our shares of common stock could increase significantly. In addition, the issuance of
shares upon exercise of the Warrants will cause immediate and substantial dilution to our stockholders. For example, if the maximum aggregate of 1,542,317,700 shares of common stock issuable upon exercise of the Warrants were issued, the ownership
interest of our existing stockholders, other than the holders of the Warrants whose ownership interests would materially increase, would be correspondingly diluted by approximately 99%.

3

The price of our common stock may decline or be depressed as a result of short sales. There is an increased potential for short sales of our common stock due to the sale of shares of our common stock pursuant to the Purchase Agreement, which could materially and adversely affect the market price of our common stock. When an investor sells stock that it does not own, it is known as a short sale. The short selling investor, anticipating that the price of the stock will go down, intends to buy stock to cover its sale at a later date. If the price of the stock goes down, the short selling investor will profit to the extent of the difference between the price at which it originally sold it less its later purchase price. The Purchase Agreement does not contain a prohibition against short sales by the selling stockholders, including between the date that the March PIPE Financing was consummated and the date that the Warrant Stockholder Approval (as defined below) is obtained, if at all. As such, receipt of the Warrant Stockholder Approval and, in particular the large number of shares of common stock then issuable upon exercise of the Common Warrants and the exercise price adjustment provisions in the Common Warrants, could encourage short sales of our common stock by the selling stockholders. When and if the Warrant Stockholder Approval is obtained, significant amounts of such short selling could place further downward pressure on the market price of our common